Kura Oncology
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Kura Oncology and other ETFs, options, and stocks.About KURA
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias.
CEOTroy E. Wilson
CEOTroy E. Wilson
Employees192
Employees192
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded2014
Founded2014
Employees192
Employees192
KURA Key Statistics
Market cap918.03M
Market cap918.03M
Price-Earnings ratio-4.12
Price-Earnings ratio-4.12
Dividend yield—
Dividend yield—
Average volume1.51M
Average volume1.51M
High today$10.63
High today$10.63
Low today$10.22
Low today$10.22
Open price$10.40
Open price$10.40
Volume1.67M
Volume1.67M
52 Week high$12.49
52 Week high$12.49
52 Week low$5.41
52 Week low$5.41
Stock Snapshot
With a market cap of 918.03M, Kura Oncology(KURA) trades at $10.59. The stock has a price-to-earnings ratio of -4.12.
During the trading session on 2025-12-15, Kura Oncology(KURA) shares reached a daily high of $10.63 and a low of $10.22. At a current price of $10.59, the stock is +3.7% higher than the low and still -0.3% under the high.
Trading activity shows a volume of 1.67M, compared to an average daily volume of 1.51M.
The stock's 52-week range extends from a low of $5.41 to a high of $12.49.
The stock's 52-week range extends from a low of $5.41 to a high of $12.49.
Analyst ratings
87%
of 15 ratingsBuy
86.7%
Hold
13.3%
Sell
0%
People also own
Based on the portfolios of people who own KURA. This list is generated using Robinhood data, and it’s not a recommendation.